https://www.biorxiv.org/content/10.1101/2020.10.29
Post# of 72440
All IPIX longs should become very familiar w/ the Full Text version of Dr Arthie's paper....one should not OVERLOOK the following key statement she makes....
""Approximately 15 percent of COVID-19 patients will develop lung injury, including severe respiratory distress that can progress to Acute Respiratory Distress Syndrome (ARDS), often requiring prolonged ventilator support and leading to death.5 Intensive care units, hospitals and health care systems risk becoming overwhelmed by critically ill COVID-19 patients. COVID-19 itself is characterized by a heightened inflammatory component, with several pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, strongly upregulated in infected individuals.6, 7, 8 The prevalence of secondary bacterial infections,9, 10, 11, 12 which can occur in up to 20 percent of cases among hospitalized patients, reinforces the need for a multi-pronged treatment approach that can address the complexities of COVID-19.""
I honestly think the CC, the Binding site interference, the ANTI Microbial activity hopefully In Vivo against HOSPITAL BUGS like Klebsiella a problematic (Gram-) pathogen typical in Pneumonias...will be as important as the ANTi Viral Effects of BRIL...the VALUE of which must be fully appreciated by the SCOPE OF ITS TOTAL ACTIVITY!
RP